TCR2 Therapeutics Snags $125 Million To Expand T-Cell Program By Sam | March 20, 2018 TCR2 Therapeutics has raised $125 million in Series B financing to advance two T-Cell receptor (TCR) programs through clinical proof-of-concept. Source: BioSpace Posted in BioPharma